最新动态
概要
2019年6月3日
公司命名变更

本公司的英文名称已由 "New B Innovation Limited" 变更为 "New Beta Innovation Limited",自二零一九年六月三日起生效。此外,公司的中文名称 "新行健医药科技有限公司" 则维持不变。

请知悉是次命名变更是不会影响公司架构以及本公司对外已签署的合同及协议书。

2019年1月11日
Commencement of FiH Healthy Volunteer Study

The First-in-Human (FiH) healthy volunteer study to evaluate safety on the use of YQ23 has commenced on 11 Jan 2019. This study is mainly to assess the safety, tolerability and pharmacokinetics (PK - the amount of study drug in the blood) of ascending single dose of YQ23 in healthy male and female subjects. The clinical trial is conducted at a Phase 1 centre in UK and will enroll approximately 40 subjects.

2016年7月11日
Approval of Clinical Trial Application in HK

New Beta Innovation receives approval from the Hong Kong Department of Health (DoH) to proceed with a Phase 1 Clinical Trial (First-in-Patient) of YQ23 in patients with advanced tumors.

2016年3月21日
EMA Orphan Medicinal Product Designation

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of oesophageal cancer.

2015年10月13日
Approval of Clinical Trial Application in UK

New Beta Innovation receives UK Medicines and Healthcare products Regulatory Agency (MHRA) approval to proceed with a Phase 1 Clinical Trial (First-in-Human) of YQ23 in healthy volunteers.

2014年11月19日
EMA Orphan Medicinal Product Designation

YQ23 has been granted the Orphan Medicinal Product Designation by the EMA for the treatment of hepatocellular carcinoma.

× 我们使用网站信标(页面标记)及小型文字档案(cookies)来改进网站及为您提供最佳的网站服务与体验。如果您继续浏览本网站,即表示您接受我们使用小型文字档案(cookies)。